Bright Uro develops the investigational Glean™ Urodynamics System, a comprehensive platform designed to enable wireless, catheter-free urodynamics monitoring to improve patient comfort and clinical decision-making. The system includes single-use disposable sensors, male and female insertion tools, a reusable uroflowmeter, and multiple software apps. In just 15 months after securing an exclusive IP license from the Cleveland Clinic, the company built, tested, and manufactured the complex system. Bright Uro is expanding its senior leadership team with hires including Suranjan Roychowdhury, Ph.D. as Chief Product Development Officer and Casey Kanel as Chief Commercial Officer. The company plans to use new funding to achieve FDA 510(k) clearance for Glean and to launch the product in the U.S. in 2024. Bright Uro is based in Irvine, Calif. Bright Uro develops the investigational Glean Urodynamics System, a wireless, catheter-free solution intended to improve accuracy, comfort, and ambulatory data collection for urodynamic testing. The Glean system includes an insertion tool, a Bluetooth-enabled pressure sensor housed in a flexible silicone tube, a clinician/patient software app, and a uroflowmeter. Bright Uro aims to move the urodynamics exam out of the urologist’s office and into patients’ homes to reduce cost and improve diagnostic quality. The company has exclusive rights to the catheter-free method via a licensing agreement with Cleveland Clinic for technology developed with the Department of Veterans Affairs, Case Western Reserve University, and Parker Hannifin Corporation. Bright Uro launched with seed financing and a government grant, positioning it to advance the investigational system through development and clinical validation. The company is based in Aliso Viejo, Calif.

Total raised

$29M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2023